An interventional study of Microport CardioFlow Mitral Valve Replacement System in Degenerative Mitral Regurgitation, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Not yet recruiting at 3 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.
Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 13th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 40 of the 45 other live ones, and was the 54th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18+
Mitrassist Lifesciences Limited Co., Ltd. · Sites in China
Ages 18+
Shanghai HeartEpoch Medical Technology Co., Ltd · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 152 is above the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 127 across the 40 interventional studies, 1,000 across the 17 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai MicroPort CardioFlow Medtech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
Shanghai MicroPort CardioFlow Medtech Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
MicroPort Scientific Corporation has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
8 of the studies in Mitral Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06162780Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTEER for Severe DMR of Low to Intermediate Surgery Risk | 2026-12 |
| NCT07632794Mi ChenArtificial Intelligence Assisting Transcatheter Mitral Edge-to-Edge Repair | 2026-12-31 |
| NCT05595187Nanjing Medical UniversityConcomitant Tricuspid Repair in Patients With Left Heart Surgery | 2026-12-31 |
| NCT07243158Hangzhou Valgen Medtech Co., LtdRandomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation | 2027-06-30 |
| NCT06883864Beijing Anzhen HospitalEfficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial | 2027-08-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 57 studies in Mitral Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multi-center, single-arm study to assess the safety and effectiveness of Microport CardioFlow Transcatheter Mitral Valve Replacement system in the treatment of moderate to severe or severe degenerative mitral regurgitation and to provide the clinical evidence for product registration in China or other countries
Subjects must meet all of the following criteria to be included in the study:
Subjects will be excluded from the study if any of the following conditions are present:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with moderate to severe or severe degenerative mitral regurgitation will undergo transcatheter mitral valve replacement
Device: Microport CardioFlow Mitral Valve Replacement System
Patients will undergo transcatheter mitral valve replacement using Microport CardioFlow Mitral Valve Replacement System. The device is delivered via a transapical approach under the guidance of medical imaging equipment; the valve product loaded within the delivery system is advanced to the mitral annulus and released, thereby replacing the native mitral valve with pathological changes in function or anatomy.
Rate of cumulative all-cause mortality at 12 months post-procedure
Time frame: 12 months
Rate of cumulative all-cause mortality at 30 days, 6 months and 2-5 years post procedure
Time frame: 30 days, 6 months and 2-5 years post procedure
Rate of heart failure rehospitalization at 30 days, 6 months and 2-5 years post procedure
Time frame: 30 days, 6 months and 2-5 years post procedure
Rate of disabling and non-disabling stroke at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Rate of myocardial infarction at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Rate of major assess site and vascular complications at 30 days, 6 months and 2-5 years post procedure
Time frame: 30 days, 6 months and 2-5 years post procedure
Rate of major and above bleeding defined by MVARC at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Rate of acute kidney injury (stage 2/3) at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Rate of arrhythmias and conduction system disturbances at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Rate of permanent pacemaker implantation at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Rate of mitral valve reoperation at 30 days, 6 months and 2-5 years post procedure
Time frame: 30 days, 6 months and 2-5 years post procedure
Technical success rate defined by MVARC at immediate post procedure
Time frame: immediate post procedure
Device success rate defined by MVARC at 30 days post procedure
Time frame: 30 days post procedure
Procedural success rate defined by MVARC at 30 days
Time frame: 30 days
Bioprosthesis haemodynamic function
Mitral regurgitation (paravalvular leak and intra-valvular regurgitation)
Time frame: 30 days, 6 months, 12 months and 2-5 years
Bioprosthesis haemodynamic function
Mitral valve area
Time frame: 30 days, 6 months, 12 months and 2-5 years
Bioprosthesis haemodynamic function
Mitral valve transvalvular pressure gradient
Time frame: 30 days, 6 months, 12 months and 2-5 years
Change in NYHA classification at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Change in QoL score from baseline at 30 days, 6 months, 12 months and 2-5 years as assessed by KCCQ
Time frame: 30 days, 6 months, 12 months and 2-5 years
Change in 6 minute walk test at 30 days, 6 months, 12 months and 2-5 years
Time frame: 30 days, 6 months, 12 months and 2-5 years
Rate of device-related technical failure issues and complications defined by MVARC at 30 days, 6 months, 12 months and 2-5 years post procedure
Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2030, 37 months later.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 37 months is below that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. →